Opus Genetics在黄斑学会年会公布Opgx-Best1基因疗法1/2期研究初步临床数据

美股速递02-27

OPUS GENETICS INC于黄斑学会年度会议上首次披露了其Opgx-Best1基因治疗项目的1/2期临床试验初步结果。该研究旨在评估针对遗传性视网膜疾病的新型基因疗法的安全性与有效性。此次数据公布标志着公司在眼科基因治疗领域取得重要进展，为后续临床开发提供了关键依据。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1146253007?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-27 23:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146253007","market":"us","top_or_hot":-1,"title":"Opus Genetics在黄斑学会年会公布Opgx-Best1基因疗法1/2期研究初步临床数据","media":"美股速递","content":"<p>OPUS GENETICS INC于黄斑学会年度会议上首次披露了其Opgx-Best1基因治疗项目的1/2期临床试验初步结果。该研究旨在评估针对遗传性视网膜疾病的新型基因疗法的安全性与有效性。此次数据公布标志着公司在眼科基因治疗领域取得重要进展，为后续临床开发提供了关键依据。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Opus Genetics在黄斑学会年会公布Opgx-Best1基因疗法1/2期研究初步临床数据</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOpus Genetics在黄斑学会年会公布Opgx-Best1基因疗法1/2期研究初步临床数据\n</h2>\n\n<h4 class=\"meta\">\n\n2026-02-27 23:13 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>OPUS GENETICS INC于黄斑学会年度会议上首次披露了其Opgx-Best1基因治疗项目的1/2期临床试验初步结果。该研究旨在评估针对遗传性视网膜疾病的新型基因疗法的安全性与有效性。此次数据公布标志着公司在眼科基因治疗领域取得重要进展，为后续临床开发提供了关键依据。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IRD","symbol_name":"OPUS GENETICS INC","start_time":0,"source_url":"","article_id":"1146253007","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146253007","pubTimestamp":1772205224,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"OPUS GENETICS INC于黄斑学会年度会议上首次披露了其Opgx-Best1基因治疗项目的1/2期临床试验初步结果。该研究旨在评估针对遗传性视网膜疾病的新型基因疗法的安全性与有效性。此次数据公布标志着公司在眼科基因治疗领域取得重要进展，为后续临床开发提供了关键依据。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IRD":"OPUS GENETICS INC","BK4139":"生物科技","BK4007":"制药"},"translate_title":"Opus Genetics announces preliminary clinical data from the Opgx-Best1 gene therapy phase 1/2 study at the Macular Society annual meeting","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRD":1},"content_text":"OPUS GENETICS INC于黄斑学会年度会议上首次披露了其Opgx-Best1基因治疗项目的1/2期临床试验初步结果。该研究旨在评估针对遗传性视网膜疾病的新型基因疗法的安全性与有效性。此次数据公布标志着公司在眼科基因治疗领域取得重要进展，为后续临床开发提供了关键依据。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1146253007","isCrawlerRequest":true}